Showing 7291-7300 of 8649 results for "".
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- Kala Pharmaceuticals Submits of Investigational NDA for KPI-012 for the Treatment of Persistent Corneal Epithelial Defecthttps://modernod.com/news/kala-pharmaceuticals-submits-of-investigational-nda-for-kpi-012-for-the-treatment-of-persistent-corneal-epithelial-defect/2481262/Kala Pharmaceuticals announced the submission of an investigational new drug application (NDA) to the FDA for KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a phase 2b cli
- BTIG to Host Ophthalmology Day on November 29, 2022https://modernod.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
- Bloomberg: Novartis Considering Sale of Ophthalmology Unithttps://modernod.com/news/bloomberg-novartis-considering-sale-of-ophthalmology-unit/2481246/Novartis is considering selling its non-core assets, including its ophthalmology franchise, to raise money for cutting-edge medicines, according to a Bloomberg
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Kinarus Therapeutics Provides Strategic Updatehttps://modernod.com/news/kinarus-therapeutics-provides-strategic-update/2481226/Kinarus Therapeutics reiterated its plans to focus on clinical trials in wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis, and to refocus its capital resources and financing efforts to drive these programs. Following the discontinuation of the phase 2 KINETIC
- The Vision Council Releases Focused inSights 2022: Digital Habitshttps://modernod.com/news/the-vision-council-releases-focused-insights-2022-digital-habits/2481225/The Vision Council has released "Focused inSights 2022: Digital Habits." The survey asked respondents how they use digital devices, if they were affected by digital eyestrain, their online purchasing habits, their social media use, and their experience with telehealth for eye care. The
- Topcon Offers Maestro2 OCT Certification Coursehttps://modernod.com/news/topcon-offers-maestro2-oct-certification-course/2481213/Topcon Healthcare has announced the new